China’s growing pipeline of novel drug candidates is expected to draw increased attention from global pharmaceutical companies and investors scouting for licensing opportunities, as the country’s clinical trial capacity has expanded to match those in the US.That assessment was made by Shanghai-based Helen Chen, Greater China managing partner at L.E.K. Consulting, one of the most respected analysts in the mainland’s life sciences industry.“There is increased interest from multinational...